29,429 Shares in C4 Therapeutics, Inc. (NASDAQ:CCCC) Acquired by Martingale Asset Management L P

Martingale Asset Management L P purchased a new stake in C4 Therapeutics, Inc. (NASDAQ:CCCCGet Rating) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 29,429 shares of the company’s stock, valued at approximately $222,000.

Several other institutional investors have also recently added to or reduced their stakes in CCCC. Tortoise Investment Management LLC acquired a new position in C4 Therapeutics in the first quarter valued at approximately $45,000. M&T Bank Corp lifted its stake in C4 Therapeutics by 134.3% in the first quarter. M&T Bank Corp now owns 17,348 shares of the company’s stock valued at $420,000 after buying an additional 9,944 shares during the period. Swiss National Bank lifted its stake in C4 Therapeutics by 7.9% in the first quarter. Swiss National Bank now owns 28,800 shares of the company’s stock valued at $699,000 after buying an additional 2,100 shares during the period. Northwestern Mutual Wealth Management Co. lifted its stake in C4 Therapeutics by 126.5% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 14,540 shares of the company’s stock valued at $353,000 after buying an additional 8,120 shares during the period. Finally, Fox Run Management L.L.C. acquired a new position in C4 Therapeutics in the first quarter valued at approximately $217,000. 80.43% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on CCCC. Wells Fargo & Company dropped their price target on C4 Therapeutics from $12.00 to $11.00 and set an “equal weight” rating on the stock in a research note on Tuesday, November 8th. Credit Suisse Group upped their target price on C4 Therapeutics to $12.00 in a research report on Tuesday, August 9th. SVB Leerink reaffirmed an “outperform” rating on shares of C4 Therapeutics in a research report on Wednesday, October 26th. Morgan Stanley assumed coverage on C4 Therapeutics in a research report on Tuesday, October 11th. They set an “underweight” rating and a $6.00 target price on the stock. Finally, JPMorgan Chase & Co. lowered C4 Therapeutics from an “overweight” rating to a “neutral” rating and lowered their target price for the stock from $22.00 to $15.00 in a research report on Friday, November 4th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $17.11.

C4 Therapeutics Trading Down 16.2 %

Shares of C4 Therapeutics stock opened at $7.86 on Thursday. The stock has a fifty day simple moving average of $9.04 and a 200 day simple moving average of $8.96. C4 Therapeutics, Inc. has a 12-month low of $4.84 and a 12-month high of $38.37. The company has a market capitalization of $384.80 million, a P/E ratio of -3.62 and a beta of 1.97. The company has a current ratio of 7.19, a quick ratio of 7.19 and a debt-to-equity ratio of 0.03.

About C4 Therapeutics

(Get Rating)

C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma.

See Also

Want to see what other hedge funds are holding CCCC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C4 Therapeutics, Inc. (NASDAQ:CCCCGet Rating).

Institutional Ownership by Quarter for C4 Therapeutics (NASDAQ:CCCC)

Receive News & Ratings for C4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.